Stoke Therapeutics (STOK) CMO sells 14,311 shares in planned trades

Rhea-AI Filing Summary

Stoke Therapeutics, Inc.’s Chief Medical Officer, Barry Ticho, reported an option exercise and related share sales. He exercised a stock option for 1,365 shares of common stock at $2.19 per share and then sold a total of 14,311 shares in open-market transactions at prices between $29.99 and $33.855 per share.

The filing notes that part of the activity was an issuer-mandated sale to cover tax withholding tied to restricted stock unit vesting, and that transactions were executed under a Rule 10b5-1 trading plan adopted on November 19, 2025. Following these transactions, Ticho directly holds 40,702 shares of Stoke Therapeutics common stock, with the reported option now fully vested and exercisable.

Insights

Insider transactions analyst

CMO exercised options and sold shares, mainly via pre-planned trades.

The Chief Medical Officer of Stoke Therapeutics, Barry Ticho, exercised 1,365 stock options at $2.19 per share and reported selling 14,311 common shares at weighted-average prices mostly in the low-$30s over March 17–19, 2026.

A footnote explains that some shares were sold to satisfy tax withholding obligations related to restricted stock unit vesting, which is a mechanical event rather than a discretionary sale. Another footnote states that the transactions were executed under a Rule 10b5-1 trading plan adopted on November 19, 2025, indicating they were pre-scheduled.

After these trades, Ticho holds 40,702 common shares directly, and the option referenced is fully vested and exercisable. The combination of tax-related sales and a pre-arranged trading plan suggests these are largely routine liquidity and compensation events, rather than a strong new signal about his view of the stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ticho Barry

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S(1)		3,577	D	$32.7394(2)	50,071	D
Common Stock	03/17/2026		S(1)		2,587	D	$33.3754(3)	47,484	D
Common Stock	03/18/2026		S(1)		6,100	D	$31.2838(4)	41,384	D
Common Stock	03/18/2026		S(1)		483	D	$31.7888(5)	40,901	D
Common Stock	03/18/2026		S(1)		103	D	$32.85	40,798	D
Common Stock	03/19/2026		M(6)		1,365	A	$2.19	42,163	D
Common Stock	03/19/2026		S(6)		1,461	D	$29.99	40,702	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.19	03/19/2026		M(6)			1,365	(7)	12/11/2028	Common Stock	1,365	$0	83,035	D

Explanation of Responses:

1. The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive.

5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive.

6. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.

7. The option is fully vested and exercisable.

	/s/ Jonathan Allan, Attorney-in-Fact	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider stock transactions did Stoke Therapeutics (STOK) CMO report?

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, reported exercising 1,365 stock options at $2.19 per share and selling 14,311 shares of common stock around the low-$30 range over March 17–19, 2026, according to the Form 4 filing.

How many STOK shares did Stoke Therapeutics CMO Barry Ticho sell?

Barry Ticho reported selling 14,311 shares of Stoke Therapeutics common stock. The Form 4 shows multiple open-market sales across several tranches at weighted-average prices generally between the high-$20s and mid-$30s per share during March 2026 trading days.

Were Barry Ticho’s STOK share sales under a Rule 10b5-1 trading plan?

Yes. A footnote states the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2025. Such plans pre-schedule trades, meaning timing is predetermined and typically reflects routine portfolio or compensation management rather than opportunistic market timing.

How many Stoke Therapeutics (STOK) shares does the CMO hold after these trades?

Following the reported transactions, Barry Ticho directly holds 40,702 shares of Stoke Therapeutics common stock. The filing also notes that the related stock option is fully vested and exercisable, indicating he retains an ongoing equity stake beyond the shares sold.

Were any of the STOK share sales related to tax withholding for Barry Ticho?

Yes. One footnote explains that part of the reported transaction represents an issuer-mandated sale to satisfy tax withholding obligations from vesting and settlement of restricted stock units. These tax-driven sales are mechanical events and not discretionary open-market sales for investment reasons.

What option exercise did Stoke Therapeutics’ CMO report in the Form 4?

The Form 4 shows Barry Ticho exercised a stock option covering 1,365 shares of Stoke Therapeutics common stock at an exercise price of $2.19 per share. The option is described as fully vested and exercisable, and the exercise converted the derivative position into common shares.